TABLE 3.
Days after onset | n | IgA+ | IgG+ | IgM+ | RNA+ | IgG+IgM+ | IgA+IgG+ | RNA+ or IgG+IgM+ | RNA+ or IgA+IgG+ |
---|---|---|---|---|---|---|---|---|---|
1–7 | 148 | 67 | 60 | 22 | 96 | 20 | 49 | 104 | 123 |
45.27% | 40.54% | 14.86% | 64.86% | 13.51% | 33.11% | 70.27% | 83.11% | ||
8–14 | 150 | 114 | 117 | 64 | 81 | 64 | 103 | 116 | 139 |
76.00% | 78.00% | 42.67% | 54.00% | 42.67% | 68.67% | 77.33% | 92.67% | ||
15–21 | 105 | 100 | 102 | 79 | 48 | 78 | 99 | 92 | 102 |
95.24% | 97.14% | 75.24% | 45.71% | 74.29% | 94.29% | 87.62% | 97.14% | ||
22–28 | 99 | 94 | 98 | 77 | 26 | 77 | 93 | 85 | 96 |
94.95% | 98.99% | 77.78% | 26.26% | 77.78% | 93.94% | 85.86% | 96.97% |
Abbreviations: +, positive results; IgM+IgG+, co‐seroconversion of IgM and IgG; IgA+IgG+, co‐seroconversion of IgA and IgG.